Earnings summaries and quarterly performance for Tilray Brands.
Executive leadership at Tilray Brands.
Board of directors at Tilray Brands.
Research analysts who have asked questions during Tilray Brands earnings calls.
Aaron Grey
Alliance Global Partners
4 questions for TLRY
Also covers: AFCG, AGFY, CGC +22 more
Pablo Zuanic
Zuanic & Associates
4 questions for TLRY
Also covers: ACB, AFCG, CGC +14 more
FG
Frederico Gomes
ATB Capital Markets
3 questions for TLRY
Also covers: AAWH, ACB, AYRWF +9 more
MB
Matt Bottomley
Canaccord Genuity Group Inc.
3 questions for TLRY
Also covers: ACB, AYRWF, CGC +7 more
ML
Michael Lavery
Piper Sandler & Co.
3 questions for TLRY
Also covers: BGS, BYND, CELH +25 more
Robert Moskow
TD Cowen
3 questions for TLRY
Also covers: BGS, BRBR, BYND +27 more
BK
Bill Kirk
Roth Capital Partners, LLC
2 questions for TLRY
Also covers: ACB, CGC, GO +7 more
Kaumil Gajrawala
Jefferies
2 questions for TLRY
Also covers: BARK, BRBR, BTMD +22 more
NA
Nicholas Anderson
Roth MKM
1 question for TLRY
Also covers: ISPR, TPB
WK
William Kirk
ROTH MKM
1 question for TLRY
Also covers: ACB, ACI, CGC +10 more
XM
Xin Ma
TD Securities
1 question for TLRY
Also covers: TAP, UL
Recent press releases and 8-K filings for TLRY.
Tilray Medical Establishes Tilray Medical Italia and Expands Product Portfolio
TLRY
New Projects/Investments
Product Launch
- Tilray Medical, a division of Tilray Brands, has established Tilray Medical Italia (formerly FL Group) to unify its European medical cannabis platform and strengthen its presence in Italy.
- This initiative includes an expanded portfolio of medical cannabis products, approved by the Italian Ministry of Health, for distribution via hospital and pharmacy channels.
- Tilray Medical Italia's operations are supported by a partnership with Molteni Farmaceutici, a leading Italian pharmaceutical company.
- The product offerings include EU-GMP certified medical cannabis flowers (e.g., THC 25%) and oils (e.g., THC10:CBD10).
Jan 22, 2026, 2:28 PM
Tilray Brands Reports Record Q2 2026 Net Revenue and Reaffirms FY 2026 Adjusted EBITDA Guidance
TLRY
Earnings
Guidance Update
New Projects/Investments
- Tilray Brands reported record Q2 net revenue of $218 million and an adjusted EBITDA of $8.4 million for Q2 2026, with a reported reverse stock split adjusted EPS loss of $0.02.
- The company's balance sheet strengthened, ending the quarter with approximately $292 million in cash and marketable securities and achieving a net cash position exceeding its debt by almost $30 million.
- Revenue growth was primarily driven by international operations, with global cannabis revenue increasing to $68 million and distribution net revenue growing 26% year-over-year to $85.3 million.
- Tilray reaffirmed its full-year 2026 Adjusted EBITDA guidance of $62-$72 million.
- The company is strategically positioned for the U.S. cannabis rescheduling to Schedule III, focusing on a federally compliant medical cannabis framework, with Tilray Medical globally expected to generate approximately $150 million on an annual run rate.
Jan 8, 2026, 9:30 PM
Tilray Brands Announces Q2 2026 Financial Results and Reaffirms Full-Year Guidance
TLRY
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Tilray Brands reported record Q2 net revenue of $218 million, adjusted EBITDA of $8.4 million, and a reverse stock split adjusted EPS loss of $0.02 for Q2 2026.
- The company strengthened its balance sheet, ending the quarter with approximately $292 million in cash and marketable securities and a net cash position exceeding debt by almost $30 million.
- Revenue growth was driven by a 51% sequential increase in international cannabis revenue to $20 million and a 26% year-over-year increase in distribution net revenue to $85.3 million.
- Tilray reaffirmed its full-year 2026 adjusted EBITDA guidance of $62-$72 million.
- The company is strategically prepared for the potential federal rescheduling of cannabis in the U.S., focusing on medical cannabis and leveraging its existing Tilray Medical U.S. platform.
Jan 8, 2026, 9:30 PM
Tilray Brands Reports Record Q2 2026 Net Revenue and Reaffirms Full-Year Adjusted EBITDA Guidance
TLRY
Earnings
Guidance Update
New Projects/Investments
- Tilray Brands reported record Q2 2026 net revenue of $217.5 million and an adjusted EBITDA of $8.4 million, with a reverse stock split adjusted EPS loss of $0.02.
- The company ended the quarter with approximately $292 million in cash and marketable securities, achieving a net cash position exceeding its debt by almost $30 million.
- Global cannabis revenue increased to $67.5 million, driven by a 36% year-over-year and 51% sequential growth in international cannabis revenue to $20 million. Distribution net revenue also grew 26% year-over-year to $85.3 million.
- Tilray Brands reaffirmed its full-year 2026 adjusted EBITDA guidance of $62 million-$72 million.
- The company is strategically positioned for the U.S. cannabis rescheduling to Schedule III, focusing on leveraging its medical cannabis platform and expertise.
Jan 8, 2026, 9:30 PM
Tilray Brands Reports Record Q2 Fiscal 2026 Net Revenue and Reaffirms Full-Year Adjusted EBITDA Guidance
TLRY
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Tilray Brands reported record net revenue of $217.5 million for the second fiscal quarter ended November 30, 2025, driven by a 36% increase in international medical cannabis revenue and a 6% increase in Canadian adult-use cannabis revenue.
- The company achieved a net cash position of $27.4 million and grew its cash and marketable securities balance to $291.6 million as of November 30, 2025.
- Tilray Brands reaffirmed its full-year fiscal 2026 Adjusted EBITDA guidance of $62 million to $72 million.
- Net loss improved by $41.8 million to $(43.5) million, with net loss per share improving to $(0.41) for the quarter ended November 30, 2025.
Jan 8, 2026, 9:20 PM
Tilray Brands Reports Q2 Fiscal 2026 Results, Achieves Net Cash Position, and Reaffirms FY2026 Adjusted EBITDA Guidance
TLRY
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Tilray Brands reported net revenue of $217.5 million for the second fiscal quarter ended November 30, 2025, marking a 3% increase compared to the prior year period.
- The company achieved a net cash position of $27.4 million as of November 30, 2025, and held $291.6 million in cash and marketable securities.
- Tilray reaffirmed its Adjusted EBITDA outlook for Fiscal 2026 at $62 million – $72 million.
- Net loss improved to $(43.5) million from $(85.3) million in the prior year period, with net loss per share improving to $(0.41).
Jan 8, 2026, 9:05 PM
Tilray establishes U.S. medical cannabis operations following federal rescheduling
TLRY
New Projects/Investments
Product Launch
- Tilray Medical, a division of Tilray Brands, confirmed its strategic framework to advance U.S. medical cannabis operations following federal cannabis rescheduling and related regulatory developments.
- In conjunction with these regulatory changes, Tilray announced the formation of Tilray Medical USA, Inc., to strengthen its commitment to leading medical cannabis innovation and growth in the U.S..
- Tilray's Chairman and CEO, Irwin D. Simon, supports President Trump's decision to reschedule cannabis, stating it is a constructive and necessary evolution of U.S. federal policy and a significant catalyst for positive change.
- Tilray Medical plans to introduce medical-grade cannabis products in targeted therapeutic formats in the U.S., leveraging its experience from over 200 registered medical cannabis products and 500,000 registered patients globally.
Dec 18, 2025, 7:07 PM
Tilray Brands announces implementation of 1-for-10 reverse stock split
TLRY
Delisting/Listing Issues
Proxy Vote Outcomes
- Tilray Brands, Inc. is implementing a one-for-ten reverse stock split of its common stock.
- The reverse stock split will become legally effective on December 1, 2025, at 4:01 p.m. Eastern Standard Time, with shares trading on a split-adjusted basis starting December 2, 2025, under the existing trading symbol "TLRY" and with the new CUSIP number 88688T209.
- The company expects the split to align its number of shares outstanding with companies of similar size and scope, make Tilray more attractive to institutional shareholders, and reduce expenditures associated with its Annual Meeting of Stockholders by up to $1 million annually.
- As a result of the split, the number of outstanding common shares will reduce from approximately 1.16 billion to 116 million, and stockholders will receive cash in lieu of any fractional shares.
Nov 26, 2025, 9:10 PM
Tilray Brands: Medicare CBD Coverage Initiative Announced
TLRY
New Projects/Investments
Revenue Acceleration/Inflection
- The Centers for Medicare & Medicaid Services (CMS) is planning an initiative to make cannabidiol (CBD) treatments eligible for coverage under Medicare for certain senior patients, particularly those receiving cancer treatments or palliative care.
- This development has sparked a rally in cannabis stocks, including Tilray Brands (TLRY), and is anticipated to provide a significant new revenue stream for the company.
- Tilray Brands (TLRY) currently holds a consensus Moderate Buy rating from Wall Street analysts, with an average price target implying a potential 92% upside.
Nov 26, 2025, 6:50 PM
Tilray Brands Highlights Market Leadership in Canadian Cannabis on Legalization Anniversary
TLRY
Revenue Acceleration/Inflection
New Projects/Investments
- Tilray Brands celebrated the seventh anniversary of cannabis legalization in Canada on October 17, 2025, having invested over C$1 billion in Canadian infrastructure and paid approximately C$700 million in excise taxes since legalization on October 17, 2018.
- In Q1FY26, Tilray's Canadian Cannabis business delivered strong results, reinforcing its position as Canada's largest legal cannabis company by revenue.
- The company holds the #1 sales position in pre-rolls, beverages, oils, and chocolate edibles, and became #1 in flower by the end of Q1FY26, with its XMG and Mollo brands commanding over 40% market share in THC beverages.
- Tilray operates 5 million square feet of advanced cannabis cultivation facilities with a current production of 210 metric tons.
Oct 17, 2025, 11:00 AM
Quarterly earnings call transcripts for Tilray Brands.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more